


Synthesis of Uridine 5'-diphosphoiduronic Acid: A Potential Substrate for the Chemoenzymatic Synthesis of Heparin

Michel Weïwer,[†] Trevor Sherwood,[†] Dixy E. Green,[‡] Miao Chen,[§] Paul L. DeAngelis,[‡] Jian Liu,[§] and Robert J. Linhardt^{*,†,||}

Department of Chemistry and Chemical Biology, Department of Chemical and Biological Engineering, and Department of Biology, Rensselaer Polytechnic Institute, 110 Eighth Street, Troy, New York 12180, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., Oklahoma City, Oklahoma, and University of North Carolina School of Pharmacy, Division of Medicinal Chemistry and Natural Products, CB no. 7360 Beard Hall, Room 309, Chapel Hill, North Carolina 27599-7360

linhar@rpi.edu

Received July 1, 2008



An improved understanding of the biological activities of heparin requires structurally defined heparin oligosaccharides. The chemoenzymatic synthesis of heparin oligosaccharides relies on glycosyltransferases that use UDP-sugar nucleotides as donors. Uridine 5'-diphosphoiduronic acid (UDP-IdoA) and uridine 5'-diphosphohexenuronic acid (UDP-HexUA) have been synthesized as potential analogues of uridine 5'-diphosphoglucuronic acid (UDP-GlcA) for enzymatic incorporation into heparin oligosaccharides. Non-natural UDP-IdoA and UDP-HexUA were tested as substrates for various glucuronosyltransferases to better understand enzyme specificity.

Introduction

Glycosaminoglycans (GAGs) are an important class of therapeutic agents that engage in specific interactions with a wide variety of proteins in both the intracellular and extracellular environment.¹ Heparin, the most studied GAG, is widely used as an injectable anticoagulant and has the highest negative

charge density of any known biological molecule.² Pharmaceutical grade heparin is commonly derived from mucosal tissues of slaughtered meat animals, such as porcine intestine or bovine lung, and is a polydisperse, polycomponent, and polypharmacologic agent.³ Low molecular weight heparins (LMWHs) are rapidly replacing heparin as the clinical anticoagulant of choice. However, these LMWHs are derived from heparin and are also polydisperse mixtures, making their controlled preparation and analysis difficult. Thus, structurally defined heparin oligosaccharides are still of great interest as potential anticoagulant agents. Fondaparinux (Arixtra, GSK) and Idraparinux (Sanofi-Aventis), homogeneous pentasaccharide analogues of the ATIII binding pentasaccharide, have been chemically synthesized and

* To whom correspondence should be addressed.
[†] Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute.

[‡] Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center.

[§] University of North Carolina School of Pharmacy, Division of Medicinal Chemistry and Natural Products.


^{||} Department of Chemical and Biological Engineering and Department of Biology, Rensselaer Polytechnic Institute.

(1) Casu, B. Chapter 1, Structure and active domains of heparin. In *Chemistry and Biology of Heparin and Heparan Sulfate*; Garg, H. G., Linhardt, R. J., Hales, C. A., Eds.; Elsevier: Oxford, UK, 2005.

(2) Linhardt, R. J.; Dordick, J. S.; Deangelis, P. L.; Liu, J. *Semin. Thromb. Hemostasis* **2007**, *33* (5), 453–465.

(3) Linhardt, R. J.; Gunay, N. S. *Semin. Thromb. Hemostasis* **1999**, *3*, 5–16.

SCHEME 1. Retrosynthesis of UDP-IdoA



introduced into the marketplace. These drugs can reduce the side effects associated with the use of heparin, particularly the risk for heparin-induced thrombocytopenia (HIT). Unfortunately, the chemical synthesis of Fondaparinux is both complicated and costly.⁴ Therefore, the development of new strategies to enable the efficient, high-yield, and stereocontrolled synthesis of homogeneous heparin-like oligosaccharides is of major importance.

Heparin is composed of alternating (1→4) linked α -L-IdoA or β -D-GlcA and β -D-GlcN units, which are diversely sulfonated. The uronic acid portion of heparin consists of approximately 80–90% of α -L-IdoA units and only 10–20% of β -D-GlcA units. The biosynthesis of heparin involves glycosyltransferases that successively add a *N*-acetylglucosamine unit (GlcNAc) from UDP-GlcNAc and a glucuronic acid unit (GlcA) from UDP-GlcA. The GlcA residues of the polysaccharide precursor are subsequently C-5 epimerized to form iduronic acid (IdoA) through the action of a C-5 epimerase. C-5 epimerases involved in heparin biosynthesis act on GlcA residues flanked by *N*-sulfoglucosamine residues.⁵ This enzyme specificity reduces access to well-defined, unnatural structures. Using the completely controlled, glucuronosyltransferase-based, introduction of IdoA residues might be possible using the unnatural analogue UDP-IdoA. The glucuronosyltransferase-based transfer of UDP-IdoA would allow access to many natural and unnatural sequences.

The availability of well-defined heparin oligosaccharides should provide an improved understanding of the important interactions that occur between heparin and proteins. Synthetic chemists have developed a variety of synthetic methodologies for accessing GAG oligosaccharides.⁶ However, while these multistep chemical strategies display elegant chemistry, they result in products that are simply too expensive. The chemoenzymatic synthesis of heparin oligosaccharides represents an interesting alternative to the complex chemical syntheses and purification processes. Indeed, enzymatic and chemoenzymatic strategies have been developed in the past few years and proven to be efficient, relying on the unique capacities of enzymes (glycosyltransferases, sulfotransferases, epimerases, etc.) to catalyze regiospecific and stereospecific transformations.⁷

During the past decade, several unnatural UDP-hexamines have been synthesized and used as substrates or inhibitors of hexosamine glycosyltransferases.⁸ UDP-*N*-trifluoroacetylglucosamine (UDP-GlcNTFA), for example, is accepted as a substrate in place of UDP-GlcNAc by the “core-2” GlcNAc transferase (EC 2.4.1.102) in the biosynthesis of *O*-linked glycoproteins, and by the GlcNAcT-V transferase (EC 2.4.1.155), a key biosynthetic enzyme controlling the branching pattern of cell surface complex Asn-linked oligosaccharides.⁹ However, unnatural analogues of UDP-GlcA have not been investigated as potential substrates of glucuronosyltransferases.

In this work, we synthesize UDP-IdoA **1**, a potential unnatural substrate of glucuronosyltransferases, which would allow the

direct and controlled enzymatic introduction of IdoA units into a growing oligosaccharide. This unnatural substrate might also be useful for the study of the specificity of various glucuronosyltransferases.

Results and Discussion

Several strategies have been developed for the synthesis of UDP-sugar nucleotides.¹⁰ Among these, the Khorana–Moffatt procedure,¹¹ involving the coupling of a sugar monophosphate with uridine 5'-monophosphomorpholidate 4-morpholine-*N,N'*-dicyclohexylcarboxamidinium salt (UMP-morpholidate), is still the preferred route. The retrosynthesis of UDP-IdoA is shown in Scheme 1.

L-IdoA is a rare sugar and is not commercially available. The efficient synthesis of L-IdoA has been a major concern for researchers synthesizing heparin oligosaccharides, and thus a wide variety of strategies have been developed for its preparation. Inversion by nucleophilic substitution at C-5 starting from 3-*O*-benzyl-1,2-isopropylidene- α -D-glucopyranose¹² or D-glucurono-6,3-lactone,¹³ radical reduction of

(4) Sinay, P.; Jacquinet, J.-C. *Carbohydr. Res.* **1984**, *132*, C5–C9.

(5) Kusche, M.; Hannesson, H. H.; Lindahl, U. *Biochem. J.* **1991**, *275*, 151–158.

(6) (a) Karst, N. A.; Linhardt, R. J. *Curr. Med. Chem.* **2003**, *10*, 1993–2031.

(b) Avci, F. Y.; Karst, N. A.; Linhardt, R. J. *Curr. Pharm. Res.* **2003**, *9*, 2323–2335. (c) Van Boeckel, C. A. A.; Petitou, M. *Angew. Chem., Int. Ed. Engl.* **1993**, *32*, 1671–1690. (d) Seeberger, P. H.; Haase, W.-C. *Chem. Rev.* **2000**, *100*, 4349–4393. (e) Ojeda, R.; Terenti, O.; de Paz, J.-L.; Martín-Lomas, M. *Glycoconj. J.* **2004**, *21*, 179–195. (f) Prabhu, A.; Venot, A.; Boons, G.-J. *Org. Lett.* **2003**, *5* (26), 4975–4978. (g) Yeung, B. K. S.; Chong, P. Y. C.; Petillo, P. A. *J. Carbohydr. Chem.* **2002**, *21* (7–9), 799–865.

(7) (a) Linhardt, R. J.; Weïwer, M. *Comprehensive Glycoscience, From chemistry to systems biology*; Elsevier Science: Boston, MA, 2007; Vol. 1, pp 713–746. (b) Kuberan, B.; Lech, M. Z.; Beeler, D. L.; Wu, Z. L.; Rosenberg, R. D. *Nat. Biotechnol.* **2003**, *21* (11), 1343–1346. (c) Muñoz, E. M.; Xu, D.; Avci, F.; Kemp, M. M.; Liu, J.; Linhardt, R. J. *Biochem. Biophys. Res. Commun.* **2006**, *339*, 597–602. (d) Chen, J.; Avci, F. Y.; Muñoz, E. M.; McDowell, L. M.; Chen, M.; Pedersen, L. C.; Zhang, L.; Linhardt, R. J.; Liu, J. *J. Biol. Chem.* **2005**, *280* (52), 42817–42825. (e) Lindahl, U.; Li, J.-P.; Kusche-Gullberg, M.; Salmivirta, M.; Alaranta, S.; Veromaa, T.; Emeis, J.; Roberts, I.; Taylor, C.; Oreste, P.; Zopetti, G.; Naggi, A.; Torri, G.; Casu, B. *J. Med. Chem.* **2005**, *48*, 349–352. (f) Sismey-Ragatz, A. E.; Green, D. E.; Otto, N. J.; Rejzek, M.; Field, R. A.; DeAngelis, P. L. *J. Biol. Chem.* **2007**, *282* (39), 28321–28327.

(8) (a) Busca, P.; Martin, O. R. *Tetrahedron Lett.* **2004**, *45*, 4433–4436. (b) Lazarevic, D.; Thiem, J. *Carbohydr. Res.* **2002**, *337*, 2187–2194. (c) Chang, R.; Vo, T.-T.; Finney, N. S. *Carbohydr. Res.* **2004**, *341*, 1998–2004. (d) Busca, P.; Piller, V.; Piller, F.; Martin, O. R. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1853–1856. (e) Gross, B. J.; Kraybill, B. C.; Walker, S. J. *Am. Chem. Soc.* **2005**, *127*, 14588–14589. (f) Losey, H. C.; Jiang, J.; Biggins, J. B.; Oberthür, M.; Ye, X.-Y.; Dong, S. D.; Kahne, D.; Thorson, J. S.; Walsh, C. T. *Chem. Biol.* **2002**, *9*, 1305–1314.


(9) Sala, R. F.; MacKinnon, S. L.; Palcic, M. M.; Tanner, M. E. *Carbohydr. Res.* **1998**, *306*, 127–136.

(10) (a) Palmacci, E. R.; Plante, O. J.; Seeberger, P. H. *Eur. J. Org. Chem.* **2002**, 595–606. (b) Arlt, M.; Hinds Gaul, O. *J. Org. Chem.* **1995**, *60*, 14–15. (c) Hanessian, S.; Lu, P.-P.; Ishida, H. *J. Am. Chem. Soc.* **1998**, *120*, 13296–13300. (d) Ernst, C.; Klaffke, W. *Tetrahedron Lett.* **2001**, *42*, 2973–2975.


(11) Roseman, S.; Distler, J. J.; Moffatt, J. G.; Khorana, H. G. *J. Am. Chem. Soc.* **1961**, *83*, 659–663.

(12) (a) Barroca, N.; Jacquinet, J.-C. *Carbohydr. Res.* **2000**, *329*, 667–679. (b) Van Boeckel, C. A. A.; Beetz, T.; Vos, J. N.; De Jong, A. J. M.; Van Aelst, S. F.; Van den Bosch, R. H.; Mertens, J. M. R.; Van der Vlugt, F. A. *J. Carbohydr. Chem.* **1985**, *4*, 293–321.

SCHEME 2. Use of a Sulfide Iduronic Acid Type Donor



SCHEME 3. MacDonald's Phosphorylation of Iduronic Acid Type Donor 5



5-bromouronate,¹⁴ functionalization of Δ^4 -uronic acid species,¹⁵ stereoselective addition on D-xylo-dialose,¹⁶ epimerization of D-GlcA derivatives,¹⁷ and diastereoselective hydroboration of exoglucals¹⁸ have shown good results. Compound **4** (Scheme 2) was first synthesized as described by Ke et al. in 31% overall yield over 5 steps from the inexpensive D-glucurono-6,3-lactone.¹³

We initially attempted to prepare the monophosphate **3** through the activation of the anomeric position of compound **4** as a phenyl sulfide.¹⁹ According to a procedure developed by Bonnaffé,²⁰ peracetylation of compound **4** was performed in the presence of acetyl chloride, pyridine, and a catalytic amount of dimethylaminopyridine (DMAP) in DCM at -40 °C to limit the potential isomerization of the pyranose ring to the corresponding furanose ring that is known to occur in the presence of pyridine/acetic anhydride. Iduronate donor **5** was then treated with thiophenol in the presence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$. The corresponding sulfide **6** was obtained in a modest yield of 37% as a 1/3 α/β mixture after purification on silica gel, but 52% of the starting material could also be recovered and reused. Glycosylation of **6** with dibenzylphosphoric acid in the presence of *N*-iodosuccinimide (NIS) gave the desired **7** in 91% yield ($\alpha/\beta = 1/4$). The β -anomer was isolated by flash chromatography in 70% yield and subjected to hydrogenolysis. During the hydrogenolysis reaction, a β -elimination of the C-4 acetate group was observed and compound **3'** was formed as the major product. Hydrogenolysis in the presence of 2 equiv of NaHCO_3 also afforded compound **3'** as the major product. β -Elimination can be acid-catalyzed or base-catalyzed, and thus neither of these reaction conditions were suitable. When we tried to first remove the ester protecting groups using Zemplén conditions, the corresponding methyl glycoside **8** was obtained.

Monophosphate **3** was next approached, using the procedure developed by MacDonald in 1962,²¹ which involves the use of an anomeric acetate and crystalline phosphoric acid at 60 °C under high vacuum (Scheme 3).

Iduronate donor **5** was treated with an excess of crystalline phosphoric acid. This strategy gave a mixture of the desired monophosphate **3** and the elimination product **3'** in 1:2 ratio. From a mechanistic point of view, we rationalized the formation of **3'** by a protonation of the C-4 acetyl group by H_3PO_4 followed by a β -elimination, which is favored in a 1,2-trans axial position, leading to the formation of **3'** and acetic acid. This mechanism is supported by the fact that phosphorylation of methyl 1,2,3,4-tetra-*O*-acetyl- β -D-glucuronate using the same conditions affords no traces of **3'**. Compounds **3** and **3'** were separated on silica gel affording monophosphate **3** as the β -anomer in 21% yield.

In an attempt to increase the yield of the phosphorylation step, another strategy was considered, in which monophosphate **3** would be obtained in two steps from **5** through the activation of the anomeric position as a bromide (Scheme 4). The bromide

(13) Ke, W.; Whitfield, D. M.; Gill, M.; Larocque, S.; Yu, S.-H. *Tetrahedron Lett.* **2003**, *44*, 7767–7770.

(14) (a) Chiba, T.; Sinay, P. *Carbohydr. Res.* **1986**, *151*, 379–389. (b) Yu, H. N.; Furukawa, J.-I.; Ikeda, T.; Wong, C.-H. *Org. Lett.* **2004**, *6* (5), 723–726.

(15) Bazin, H. G.; Kerns, R. J.; Linhardt, R. J. *Tetrahedron Lett.* **1997**, *38*, 923–926.

(16) Lubineau, A.; Gavard, O.; Alais, J.; Bonnaffé, D. *Tetrahedron Lett.* **2000**, *41*, 307–311.

(17) (a) Vlahov, I. R.; Linhardt, R. J. *Tetrahedron Lett.* **1995**, *36*, 8379–8382. (b) Schell, P.; Orgueira, H. A.; Roehrig, S.; Seeberger, P. H. *Tetrahedron Lett.* **2001**, *42*, 3811–3814.


(18) (a) Chiba, T.; Jacquinet, J.-C.; Sinay, P.; Petitou, M.; Choay, J. *Carbohydr. Res.* **1988**, *174*, 253–264. (b) Rochepeau-Jobron, L.; Jacquinet, J.-C. *Carbohydr. Res.* **1997**, *303*, 395–406.

(19) Deng, S.; Gangadharmath, U.; Chang, C.-W. T. *J. Org. Chem.* **2006**, *71*, 5179–5185.


(20) Gavard, O.; Hersant, Y.; Alais, J.; Duverger, V.; Dilhas, A.; Bascou, A.; Bonnaffé, D. *Eur. J. Org. Chem.* **2003**, 3603–3620.

(21) MacDonald, D. L. *J. Org. Chem.* **1962**, *27*, 1107–1109.

SCHEME 4. Synthesis of UDP-IdoA Using a Bromide Donor



SCHEME 5. Synthesis of UDP-Hexenuronic Acid 1'



donor **9** was obtained as the α -anomer **9- α** in 95% purity by ^1H NMR (see the Supporting Information) and in 89% yield. The desired monophosphate **3** was obtained from the bromide donor **9** in 41% yield by treatment with the tetrabutylammonium salt of phosphoric acid. The reaction was stereospecific and only the β -anomer of **3** was identified (see the Supporting Information, ^1H NMR $J_{1,P} = 7.5$ Hz and $J_{1,2} = 2.0$ Hz). Traces of the eliminated monophosphate **3'** could also be observed. Treatment of compound **3** with a catalytic amount of sodium methoxide in methanol afforded the unprotected monophosphate **2**, which was converted into its monopyridinium salt by treatment with Amberlite resin (pyridinium form). The methyl ester was kept intact to avoid problems during the coupling reaction. The monophosphate **2** was then reacted with UMP-morpholidate according to the procedure of Khorana and Moffatt. The resulting mixture was then treated with a 2:2:1 mixture of MeOH/H₂O/Et₃N to remove the methyl ester. Purification was accomplished with a BioGel P2 with 0.25 M NH₄HCO₃ as eluent, followed by desalting on BioGel P2 with water as eluent. The fractions containing UDP-IdoA were lyophilized and further purified by using a semipreparative SAX-HPLC column (linear gradient from 0 to 1 M NaCl over 50 min.) required for the removal of the uridine diphosphate dimer formed by self-condensation of UMP-morpholidate, which is a classical byproduct of the coupling reaction. After desalting on BioGel P2, the UDP-IdoA **1** target was obtained in 26% yield over 2 steps.

Using the same strategy, the unsaturated analogue of UDP-GlcA and UDP-IdoA, the UDP-HexUA **1'**, was obtained in 31% yield over 3 steps from **3'** (Scheme 5).

Enzymatic Assays. These unnatural analogues of UDP-GlcA have been tested as substrates for glycosyltransferases isolated from *Pasteurella multocida* (*PmHS1* and *PmHS2*).^{7f} UDP-IdoA could ultimately serve as a substrate for the direct and specific incorporation of IdoA units in a growing oligosaccharide to enzymatically build the heparin backbone. UDP-HexUA could serve as a potential chain terminator for the preparation of polymers having a defined molecular weight range.

Recently, Sismey-Ragatz et al. reported the enzyme-catalyzed incorporation of unnatural UDP-glucosamine derivatives to different heparosan type acceptors using the *Pasteurella multocida* heparosan synthases *PmHS1* and *PmHS2*.^{7f} These enzymes both possess two active sites, a glucosaminyltransferase site that transfers UDP-GlcNAc and a glucuronosyltransferase site that transfers UDP-GlcA to an oligosaccharide acceptor. Neither of these glycosyltransferases were able to transfer UDP-HexUA. To build polymers having the backbone of heparin (GlcN-IdoA), UDP-IdoA was used in combination with UDP-GlcNAc, in the presence of *PmHS1* or *PmHS2*, and A-F-AN as acceptor.^{7f} Radiochemical assays suggested that both *PmHS1* and *PmHS2* incorporated UDP-IdoA and UDP-GlcNAc, albeit much lower efficiency than with UDP-GlcA (~4% rate of authentic UDP-GlcA). Gel analysis of the *PmHS2* polymerization reactions without acceptor demonstrated small amounts of short polymers were generated by using the UDP-IdoA preparation (Figure 1). UDP-GlcA yielded a much greater amount of larger polymers. In another set of experiments, we tested A-F-AN as acceptor and either UDP-GlcA or UDP-IdoA as donor in combination with *PmHS2* and monitored the formation of the corresponding tetrasaccharide A-F-AN-UA.




FIGURE 1. Analysis of GAG polymers by polyacrylamide gel electrophoresis and analysis of the A-F-AN-UA tetrasaccharide by MALDI-ToF. *PmHS2* was used in three polymerization reactions containing UDP-GlcNAc and either UDP-GlcA (G), no second sugar (0), or the UDP-IdoA preparation (I). Large molecular mass polymers were formed in abundance with the authentic precursor, but the UDP-IdoA analogue resulted in smaller amounts of short chains (bracketed). The positions of hyaluronan standards are shown in sugar units (18-mer = ~1.6 kDa; 40-mer = ~8 kDa) (note: the light staining band marked with an asterisk (*) is the enzyme). MALDI-ToF spectra: top spectrum = A-F-AN + UDP-GlcA, bottom spectrum = A-F-AN + UDP-IdoA.

MALDI-ToF mass spectrometry allowed the detection of trace amounts of tetrasaccharide with the expected mass when UDP-IdoA was tested (Figure 1, A-F-AN-GlcA observed 1106.55 Da when using UDP-GlcA versus 1106.12 Da when using UDP-IdoA; the mock reaction did not possess this same peak).

While a small portion of the UDP-IdoA incorporated, it remains unclear whether the low levels of incorporation are due to (a) either UDP-IdoA or its elongation products inhibiting the synthase, or (b) the presence of trace UDP-GlcA contaminant, or (c) the formation of UDP-GlcA from UDP-IdoA through epimerization during synthase catalysis.

^3H -labeled trisaccharide (GlcN[^3H]Ac-GlcA-AnMan) was used as acceptor in the presence of *PmHS1* or *PmHS2* to help identify the uronic acid residue that is transferred when using the UDP-IdoA preparation (Figure 2), and the reactions were monitored by using PAMN-HPLC.²² ^3H -labeled trisaccharide was synthesized from a disaccharide (GlcUA-AnMan) by using *E. coli* derived KfiA and UDP-GlcNAc[^3H], where AnMan represents 2,5-anhydromannitol.²²

When UDP-GlcA was used (positive control), the desired tetrasaccharide was obtained with a very good selectivity. When UDP-IdoA was used as substrate, the conversion was very low, but a small peak corresponding to the tetrasaccharide was obtained. These products were treated with glucuronidase and iduronidase to identify the nature of the uronic acid unit incorporated.²³ Both tetrasaccharide products were glucuronidase-sensitive but were iduronidase-insensitive. Thus, the UDP-IdoA could not be incorporated as IdoA into oligosaccharides with use of *PmHS1* or *PmHS2*. While trace amounts of UDP-GlcA contaminant could be present in the synthetic preparation, it could not be detected with NMR or SAX-HPLC. Alternatively, UDP-GlcA might be formed from UDP-IdoA through unexpected and hitherto never previously observed C-5 epimerization during synthase catalysis. A wider library of UDP-GlcA analogues is needed to understand the specificity of these glycosyltransferases. The current study constitutes a preliminary study. Furthermore, it may be possible to incorporate IdoA units in a growing oligosaccharide from UDP-IdoA by modifying the




FIGURE 2. PAMN-HPLC profiles of *PmHS2* modified ^3H -labeled trisaccharide. A ^3H -labeled trisaccharide with a structure of (GlcN[^3H]Ac-GlcUA-AnMan) was incubated with *PmHS2* and UDP-GlcA or UDP-IdoA. The product was analyzed by PAMN-HPLC which was eluted with a linear gradient of KH_2PO_4 . Panel A shows the profile of unmodified ^3H -trisaccharide. Panel B shows the profile of ^3H -trisaccharide modified with *PmHS2* in the presence of UDP-GlcA for 2 h. Panel C shows the profile of ^3H -labeled trisaccharide modified with *PmHS2* in the presence of UDP-IdoA for 2 h. Panel D shows the profile of ^3H -labeled trisaccharide modified with *PmHS1* in the presence of UDP-IdoA overnight.

glycosyltransferase to accept such an unnatural substrate. Work is underway to generate a library of glycosyltransferase mutants to test their ability to utilize UDP-IdoA to build IdoA containing oligosaccharides.

In conclusion, two new unnatural analogues of UDP-GlcA, UDP-IdoA **1** and UDP-HexUA **1'**, were synthesized and used to study the specificity of different glucuronosyltransferases. UDP-HexUA did not serve as a substrate for the glucuronosyltransferases tested. When UDP-IdoA was used as the substrate, sugar residues were transferred but only GlcA was incorporated into the products formed. This result could be explained by the contamination of synthetic UDP-IdoA with a small amount of UDP-GlcA. Alternatively, UDP-IdoA might be isomerized to UDP-GlcA by the synthase upon transfer by a not known yet understood enzymatic process.

Experimental Section

Methyl 1,2,4-Tri-*O*-acetyl-3-*O*-pivaloyl- β -L-idopyranuronate (5). Methyl 3-*O*-pivaloyl-L-iduronate (**4**) (3.1 g, 10.6 mmol) was suspended in anhydrous CH_2Cl_2 (56 mL) under argon atmosphere at -40°C (acetone/dry ice) and 2,4-dimethylaminopyridine (130

(22) Chen, M.; Bridge, A.; Liu, J. *Biochemistry* **2006**, *45*, 12358–12365.

(23) Chen, J.; Duncan, M. B.; Carrick, K.; Pope, R. M.; Liu, J. *Glycobiology* **2003**, *13*, 785–794.

mg, 1.06 mmol), pyridine (8.66 mL, 106 mmol), and acetyl chloride (4.54 mL, 63.7 mmol) were added. After being stirred at this temperature for 10 h, the mixture was diluted with CH₂Cl₂ (150 mL) and the resulting organic phase was washed with saturated NaHCO₃, water, 1 M HCl, and water. The organic layer was dried over Na₂SO₄, filtered, and concentrated under diminished pressure. After purification on silica gel with use of a gradient of petroleum ether/ethyl acetate (85/15 to 50/50), methyl 1,2,4-tri-*O*-acetyl-3-*O*-pivaloyl- β -L-idopyranuronate (**5**) (2.88 g, 65%) was obtained. An additional mixture of **5** α /**5** β (302 mg, 7%) was also recovered (combined yield of **5** α /**5** β : 72%). ¹H NMR (500 MHz, CDCl₃) δ (ppm) 6.03 (1H, d, *J* = 2.0 Hz, H-1), 5.32 (1H, t, *J* = 4.1 Hz, H-3), 5.10 (1H, m, H-4), 5.01 (1H, ddd, *J* = 4.1 Hz, *J* = 2.0 Hz, *J* = 0.7 Hz, H-2), 4.68 (1H, d, *J* = 2.7 Hz, H-5), 3.79 (3H, s, CO₂Me), 2.14, 2.12, 2.09 (9H, 3 s, 3 OAc), 1.26 (9H, s, Piv). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 175.7, 169.4, 169.2, 168.5, 166.8 (Piv, 3 OAc and CO₂Me), 89.9 (C-1), 73.2 (C-5), 66.8 (C-3), 66.5 (C-2), 65.6 (C-4), 52.7 (CO₂Me), 38.9 (quaternary C of Piv), 27.0 (3 Me of Piv), 20.7, 20.6, 20.5 (3 Me of 3 OAc). HRMS *m/z* calcd for C₁₈H₂₆O₁₁Na [M + Na]⁺ 441.1367, found 441.1369.

Methyl 1-Phenylthio-2,4-di-*O*-acetyl-3-*O*-pivaloyl-L-idopyranuronate (6**).** Methyl 1,2,4-tri-*O*-acetyl-3-*O*-pivaloyl- β -L-idopyranuronate (**5**) (1.0 g, 2.39 mmol) was suspended in anhydrous CH₂Cl₂ (5 mL) under argon atmosphere at room temperature and freshly activated MS 4Å (200 mg), thiophenol (0.3 mL, 2.91 mmol), and BF₃·Et₂O (0.45 mL, 3.59 mmol) were added. After being stirred at this temperature for 1 day, the mixture was diluted with CH₂Cl₂ (150 mL) and the resulting organic phase was washed with cold water then saturated NaHCO₃. The organic layer was dried over Na₂SO₄, filtered, and concentrated under diminished pressure. After purification on silica gel with a gradient of petroleum ether/ethyl acetate (85/15 to 50/50), methyl 1-phenylthio-2,4-di-*O*-acetyl-3-*O*-pivaloyl-L-idopyranuronate (**6**) (413 mg, α/β = 1/3, 37%) was obtained. Further elution allowed recovery of the starting material **5** (520 mg, 52%) that could be reused.

6 α : ¹H NMR (500 MHz, CDCl₃) δ (ppm) 7.60–7.58 (2H, m, H_{Ar}), 7.33–7.31 (3H, m, H_{Ar}), 5.13 (1H, t, H-4), 5.08–5.04 (3H, m, H-2, H-3, H-5), 4.46 (1H, d, *J* = 1.8 Hz, H-1), 3.78 (3H, s, CO₂Me), 2.16, 2.09 (6H, 2 s, 2 OAc), 1.21 (9H, s, OPiv). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 175.1, 169.2, 169.1, 167.1 (Piv, 2 OAc and CO₂Me), 133.4 (C-1'), 132.1 (2C-2'), 129.1 (2C-3'), 128.1 (C-4'), 85.1 (C-1), 74.6 (C-5), 67.6 (C-3), 66.1 (C-2), 65.6 (C-4), 52.6 (CO₂Me), 38.7 (quaternary C of Piv), 27.0 (3 Me of Piv), 20.6, 20.5 (2 Me of 2 OAc). HRMS *m/z* calcd for C₂₂H₂₈O₉SNa [M + Na]⁺ 491.1346, found 491.1353.

6 β : ¹H NMR (500 MHz, CDCl₃) δ (ppm) 7.51–7.49 (2H, m, H_{Ar}), 7.32–7.27 (3H, m, H_{Ar}), 5.68 (1H, d, *J* = 2.6 Hz, H-1), 5.22 (1H, d, H-5), 5.18 (1H, t, H-3), 5.13 (1H, t, H-2), 4.99 (1H, t, H-4), 3.80 (3H, s, CO₂Me), 2.09, 2.08 (6H, 2 s, 2 OAc), 1.30 (9H, s, OPiv). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 176.1, 169.3, 169.2, 168.2 (Piv, 2 OAc and CO₂Me), 134.0 (C-1'), 131.4 (2C-2'), 129.1 (2C-3'), 127.8 (C-4'), 85.5 (C-1), 68.5 (C-5), 67.7 (C-3), 66.9 (C-2), 66.2 (C-4), 52.6 (CO₂Me), 38.9 (quaternary C of Piv), 27.0 (3 Me of Piv), 21.0, 20.8 (2 Me of 2 OAc). HRMS *m/z* calcd for C₂₂H₂₈O₉SK [M + K]⁺ 507.1086, found 507.1087.

Methyl 1-Dibenzylphospho-2,4-di-*O*-acetyl-3-*O*-pivaloyl-L-idopyranuronate (7**).** Methyl 1-phenylthio-2,4-di-*O*-acetyl-3-*O*-pivaloyl-L-idopyranuronate (**6**) (47 mg, 100 μ mol), dibenzyl phosphoric acid (57 mg, 200 μ mol), and freshly activated MS 4Å (60 mg) were suspended in anhydrous dichloroethane (1 mL) at room temperature. *N*-Iodosuccinimide (45 mg, 200 μ mol) was added and the mixture was stirred overnight. The molecular sieves was then filtered off and washed with CH₂Cl₂. The resulting organic phase was washed with saturated NaHCO₃, water, saturated Na₂S₂O₃, then water. The organic layer was dried over Na₂SO₄, filtered, and concentrated under diminished pressure. After purification on silica gel with a gradient of petroleum ether/ethyl acetate (7/3 to 1/1), methyl 1-dibenzylphospho-2,4-di-*O*-acetyl-3-*O*-pivaloyl- β -L-idopyranuronate (**7** β) (45 mg, 73%) and methyl 1-diben-

zylphospho-2,4-di-*O*-acetyl-3-*O*-pivaloyl- α -L-idopyranuronate (**7** α) (12 mg, 18%) were obtained. **7** β : ¹H NMR (500 MHz, CDCl₃) δ (ppm) 7.37–7.28 (10H, H_{Ar}), 5.84 (1H, dd, *J*_{1,P} = 6.4 Hz, *J*_{1,2} = 0.6 Hz, H-1), 5.15–5.00 (6H, m, H-3, H-4, 2CH₂ of OBn), 4.89 (1H, d, *J* = 2.4 Hz, H-5), 4.84 (1H, m, H-2), 3.70 (3H, s, CO₂Me), 2.08, 2.07 (6H, 2 s, 2 OAc), 1.17 (9H, s, Piv). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 177.3 (d, *J*_{C,P} = 6.6 Hz, Piv), 169.2 (d, *J*_{C,P} = 2.6 Hz, OAc), 168.9 (d, *J*_{C,P} = 2.4 Hz, OAc), 167.3 (CO₂Me), 135.3, 135.2 (2d, *J*_{C,P} = 7.3 Hz and *J*_{C,P} = 7.3 Hz, 2 quaternary Ar), 128.6, 128.5, 128.4, 128.0, 127.8 (10 CH_{Ar}), 94.9 (d, *J*_{C,P} = 5.6 Hz, C-1), 69.8 (d, *J*_{C,P} = 5.2 Hz, C-5), 69.5 (d, *J*_{C,P} = 5.2 Hz, C-3), 67.5 (d, *J*_{C,P} = 3.9 Hz, C-2), 66.4 (d, *J*_{C,P} = 2.5 Hz, C-4), 65.9, 65.4 (2d, *J*_{C,P} = 11.0 Hz and *J*_{C,P} = 3.7 Hz, 2CH₂ OBn), 52.6 (d, *J*_{C,P} = 2.9 Hz, CO₂Me), 38.7 (quaternary C of Piv), 26.8 (d, *J*_{C,P} = 5.7 Hz, 3 Me of Piv), 20.6, 20.5 (2d, *J*_{C,P} = 2.8 Hz and *J*_{C,P} = 2.7 Hz, 2 OAc). HRMS *m/z* calcd for C₃₀H₃₇O₁₃PNa [M + Na]⁺ 659.1864, found 659.1860.

Methyl 1-Phospho-2,4-di-*O*-acetyl-3-*O*-pivaloyl- β -L-idopyranuronate (3**).** Phosphoric acid (30 mg, 0.3 mmol) was treated with a 40 wt % aqueous solution of tetrabutylammonium hydroxide (0.6 mL, 0.9 mmol) at 0 °C in an ice bath. After 10 min the mixture was freeze-dried to afford the tetrabutylammonium phosphate (246 mg, 0.3 mmol). Methyl 1-bromo-2,4-di-*O*-acetyl-3-*O*-pivaloyl- β -L-idopyranuronate (**9**) (101 mg, 0.23 mmol) dissolved in acetonitrile (7 mL), triethylamine (32 μ L, 0.23 mmol) dissolved in acetonitrile (4 mL), and molecular sieves 3Å (250 mg) were added. This mixture was heated in refluxing acetonitrile (80 °C) for 30 min. After the mixture had cooled to rt, the molecular sieves was filtered off and washed with acetonitrile. The filtrate was evaporated under diminished pressure to afford a brown oil. After purification on silica gel with a gradient of EtOAc/MeOH (1/0 to 1/1), methyl 1-phospho-2,4-di-*O*-acetyl-3-*O*-pivaloyl- β -L-idopyranuronate (**3**) was obtained. To facilitate NMR assignment, it was then treated with Amberlite (NH₄⁺ form) in methanol to obtain the corresponding ammonium salt of **3** (46 mg, 41%). ¹H NMR (500 MHz, MeOD) δ (ppm) 5.66 (1H, dd, *J*_{1,P} = 7.5 Hz, *J*_{1,2} = 2.0 Hz, H-1), 5.14–5.05 (4H, m, H-2, H-3, H-4, H-5), 3.76 (3H, s, CO₂Me), 2.09 and 2.04 (6H, 2 s, 2 OAc), 1.25 (9H, s, Piv). ¹³C NMR (125 MHz, MeOD) δ (ppm) 178.2, 171.0, 170.8, 170.3 (Piv, 2 OAc and CO₂Me), 95.1 (d, *J*_{1,P} = 4.9 Hz, C-1), 69.1 (d, *J*_{2,P} = 10.3 Hz, C-2), 69.0 (C-4), 68.9 (C-3), 68.2 (C-5), 52.9 (CO₂Me), 39.9 (quaternary C of Piv), 27.4 (3 Me of Piv), 20.7, 20.5 (2 Me of 2 OAc). HRMS *m/z* calcd for C₁₆H₂₄O₁₃P [M – H][–] 455.0960, found 455.0956.

Methyl 1-Bromo-2,4-di-*O*-acetyl-3-*O*-pivaloyl- α -L-idopyranuronate (9**).** Methyl 1,2,4-tri-*O*-acetyl-3-*O*-pivaloyl- β -L-idopyranuronate (**5**) (120 mg, 0.287 mmol) was suspended in anhydrous CH₂Cl₂ (1 mL) at 0 °C and water (31 μ L, 1.72 mmol) followed by PBr₃ (46 μ L, 0.49 mmol) were added. After being stirred at this temperature for 10 min, the mixture was warmed to rt and vigorously stirred for 3 h. The resulting mixture was then diluted with CH₂Cl₂ (15 mL) and washed with water and saturated NaHCO₃ solution. The organic layer was dried over Na₂SO₄, filtered, and concentrated under diminished pressure to give the methyl 1-bromo-2,4-di-*O*-acetyl-3-*O*-pivaloyl- α -L-idopyranuronate (**9** α) (112 mg, 89%). This compound was used in the next step without further purification after ¹H NMR showed purity higher than 95%. ¹H NMR (500 MHz, CDCl₃) δ (ppm) 6.46 (1H, br s, H-1), 5.19 (1H, br s, H-4), 5.08–5.06 (2H, m, H-3 and H-2), 4.97 (1H, d, *J* = 1.7 Hz, H-5), 3.82 (3H, s, CO₂Me), 2.12, 2.10 (6H, 2 s, 2 OAc), 1.30 (9H, s, Piv).

Uridine 5'-Diphosphoiduronic Acid (UDP-IdoA) (1**).** Methyl 1-phospho-2,4-di-*O*-acetyl-3-*O*-pivaloyl- α -L-idopyranuronate (**3**) (18 mg, 36 μ mol) was dissolved in anhydrous MeOH (1 mL), cooled to 0 °C, and treated with a 0.5 M solution of MeONa in MeOH (0.5 mL). After 3 h at rt, the solution was cooled to 0 °C and Amberlite (H⁺ form, 250 mg) was added. After filtration, MeOH was evaporated and the resulting mixture was redissolved in water before treatment with Amberlite (PyH⁺ form). The corresponding monopyridinium salt of **2** (14 mg) was obtained after

freeze-drying. The monopyridinium salt of methyl 1-phospho- α -L-idopyranuronate (**2**) (14 mg, 36 μ mol) was dissolved in anhydrous pyridine (1 mL) and evaporated under diminished pressure. This operation was repeated 3 times. A solution of 4-morpholine *N,N'*-dicyclohexylcarboxamidinium uridine 5'-phosphomorpholidate (34 mg, 49 μ mol) in anhydrous pyridine (2 mL) was concentrated to dryness in vacuo. This operation was also repeated 3 times. A solution of the 4-morpholine *N,N'*-dicyclohexylcarboxamidinium uridine 5'-phosphomorpholidate in anhydrous pyridine (1 mL) was then added to the dry monopyridinium salt of methyl 1-phospho- α -L-idopyranuronate (**6**) followed by concentration in vacuo. The mixture was then redissolved in anhydrous pyridine (800 μ L) and stirred at rt for 5 days under argon atmosphere. Pyridine was then evaporated under reduced pressure and the mixture was treated with MeOH/H₂O/Et₃N 2:2:1 (1.5 mL) for 24 h at RT, in order to deprotect the methyl ester. The mixture was then concentrated under reduced pressure and redissolved in water. Purification was achieved on a P2 BioGel column with a 0.25 M NH₄HCO₃ solution as eluent. The fractions containing UDP-IdoA (UV at 262 nm) were pooled and lyophilized. Further purification was achieved with use of a semipreparative SAX column (20 \times 250 mm), using a linear gradient of NaCl (0 to 1 M over 50 min) at pH 3.5. After desalting on P2 BioGel, UDP-IdoA **1** (6 mg, 9.3 μ mol, 26%) was obtained as a white powder. ¹H NMR (500 MHz, D₂O) δ (ppm) 7.86 (1H, d, *J* = 8.1 Hz, H-6), 5.95–5.85 (2H, m, H-1' and H-5), 5.46 (1H, dd, *J*_{1',P} = 7.9 Hz, *J*_{1,2} = 2.9 Hz, H-1''), 4.55 (1H, d, *J* = 2.8 Hz, H-5''), 4.30–4.10 (5H, m, 2H-5', H-4', H-3', H-2'), 3.92 (1H, dd, *J* = 3.9 Hz, *J* = 2.8 Hz, H-4''), 3.79 (1H, t, *J* = 4.8 Hz, H-3''), 3.69 (1H, dd, *J* = 5.1 Hz, *J* = 2.9 Hz, H-2''). ¹³C NMR (125 MHz, D₂O) δ (ppm) 175.9 (C-6''), 166.3 (d, *J* = 22.1 Hz, C-4), 151.9 (d, *J* = 21.9 Hz, C-2), 141.6 (C-6), 102.7 (d, *J* = 10.1 Hz, C-5), 97.2 (d, *J* = 6.5 Hz, C-1''), 88.2 (d, *J* = 6.3 Hz, C-1'), 83.4 (d, *J* = 9.3 Hz, C-4'), 83.3 (d, *J* = 9.0 Hz, C-5''), 73.8 (d, *J* = 21.1 Hz, C-3'), 70.6 (d, *J* = 7.1 Hz, C-3''), 70.3 (C-4''), 69.7 (C-2''), 66.0 (d, *J* = 6.1 Hz, C-2'), 64.9 (d, *J* = 5.8 Hz, C-5'). ³¹P NMR (202.34 MHz, D₂O) δ (ppm) -10.2 (d, *J* = 20 Hz), -12.2 (d, *J* = 20 Hz). HRMS *m/z*, calcd for C₁₅H₂₁N₂O₁₈P₂ [M - H]⁻ 579.0270, found 579.0255.

Uridine 5'-Diphosphohex-4,5-enuronic Acid (1'). Following the same procedure as described above, uridine 5'-diphosphohex-4,5-enuronic acid (**1'**) was obtained (10 mg, 31%). ¹H NMR (500 MHz, D₂O) δ (ppm) 7.87 (1H, d, *J* = 8.1 Hz, H-6), 5.93 (1H, d, *J* = 4.5 Hz, H-1'), 5.90 (1H, d, *J* = 8.1 Hz, H-5), 5.82 (1H, d, *J* = 3.9 Hz, H-4''), 5.60 (1H, dd, *J*_{1',P} = 8.4 Hz, *J*_{1,2} = 5.3 Hz, H-1''), 4.30 (1H, m, H-2'), 4.21 (1H, m, H-3'), 4.16 (1H, m, H-4'), 4.13–4.10 (2H, m, H-3'', H-5'), 3.84 (1H, t, *J* = 5.0 Hz, H-2''). ¹³C NMR (125 MHz, D₂O) δ (ppm) 168.9 (C-6''), 166.63 and 166.56 (C-2 and C-4), 144.6 (C-5''), 141.5 (C-6), 107.3 (C-4''), 102.7 (C-5), 95.3 (C-1''), 88.2 (C-1'), 83.4 (C-3'), 83.3 (C-4'), 70.0 (C-2''), 69.7 (C-2'), 66.0 (C-5'), 65.1 (C-3''). ³¹P NMR (202.34 MHz, D₂O) δ (ppm) -9.98 (d, *J* = 20 Hz), -11.95 (d, *J* = 20 Hz). HRMS *m/z*, calcd for C₁₅H₁₉N₂O₁₇P₂ [M - H]⁻ 561.0164, found 561.0158.

Enzymatic Assays. Polymerization Reactions with *Pasteurella multocida* Heparosan Synthases (*PmHS1* and *PmHS2*). UDP-sugars were dissolved at 15 mM in 10 mM Tris, pH 7.2, buffer for

storage as aliquots at -80 °C. Maltose binding protein fusions of *PmHS1* or *PmHS2*, two isozymes of heparosan synthase, were employed as the catalysts.^{7f} Sugar addition reactions typically contained 50 mM Tris, pH 7.2, 1 mM MnCl₂, *PmHS1* or *PmHS2*, various amounts of UDP-GlcNAc, and either (a) UDP-GlcA (the authentic uronic acid) or (b) UDP-IdoA as noted. To measure relative incorporation rates of the two UDP-uronic acids (1 mM), radioactive UDP-[³H]GlcNAc (0.27 μ M; 0.2 μ Ci/reaction) addition into polymer by enzyme (12–15 μ g; 24 h at 30 °C) was monitored by paper chromatography.^{7f} For another proof of polymerization, reactions with nonradioactive UDP-sugars (10–25 mM each) and enzyme (46 μ g; 22 h at 30 °C) were analyzed on polyacrylamide gels with combined Alcian Blue/Silver staining.^{7f} Single sugar addition reactions with A-F-AN, a synthetic acceptor (0.5–1 mM), and synthase (6–15 μ g; 18–60 h at 22–30 °C) were used under similar conditions as polymerization assays, but only a single UDP-uronic acid (0.75–1.5 mM) was employed. Products were analyzed by MALDI-ToF mass spectrometry with ATT matrix in negative ion mode.^{7f}

Enzymatic Synthesis of a Tetrasaccharide. *PmHS2* (50 μ g) was incubated with trisaccharide (50,000 cpm) in a buffer containing 25 mM Tris (pH 7.5), 10 mM MnCl₂, 10 mM MgCl₂, and 1 μ M UDP-GlcUA or UDP-IdoUA at 37 °C for 2 h or overnight. The presence of anticipated ³H-labeled tetrasaccharide (GlcUA-GlcN[³H]Ac-GlcUA-AnMan) was determined by determining the retention time of the ³H-peak on polyamine-based anion exchange HPLC.²² Briefly, the polyamine II column (YMC) was equilibrated with ddH₂O for 10 min, and then eluted with a linear gradient of 0 to 1 M KH₂PO₄ in 60 min at 0.5 mL/min. ³H-labeled trisaccharide and tetrasaccharide were respectively eluted at around 33 and 83 mM of KH₂PO₄.

Glucuronidase/Iduronidase Treatment of the Tetrasaccharide. The resulting ³H-labeled tetrasaccharide was purified by PAMN-HPLC and desalted by dialyzing against water, using MWCO 1000 membrane. The ³H-labeled tetrasaccharide was digested with either β -glucuronidase or α -iduronidase as described previously.²³ The digested samples were reanalyzed by PAMN-HPLC to determine if the tetrasaccharide was susceptible to the digestion with either β -glucuronidase or α -iduronidase.

Acknowledgment. This work was supported by the National Institute of Health (NIH HL062244 to R.J.L.). The authors would like to thank Nigel J. Otto for the preparation of the heparosan synthases, Dr. Zhenqing Zhang for his help in acquiring NMR data, and Dr. Dmitri Zagorevski for HRMS analyses.

Supporting Information Available: ¹H and ¹³C NMR data of compounds **1**, **1'**, **3–7**, and **9** and ³¹P NMR, COSY, and HMQC of compounds **1** and **1'**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JO801409C